5 Key Takeaways

• 1

  Theialife appointed Thomas Ruggia as CEO to advance its oral therapy for pediatric myopia into phase 3 development.

• 2

  Ruggia has over 25 years of experience in ophthalmology and previously led global commercialization at Samsara Vision.

• 3

  The company is preparing to initiate phase 3 trials of ND10, a first-in-class oral therapy targeting myopia progression in children.

• 4

  ND10 is supported by over two decades of data from Denmark, showing encouraging efficacy and safety in over 1,200 treated children.

• 5

  Theialife is also developing a broader ophthalmology pipeline, including treatments for dry eye disease and wet AMD.